TTM
−$0.23
YoY change
-50.0%
5Y CAGR
—
Peak year (2025)
−$0.25
Latest annual
−$0.25
EPS (Diluted) history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: −$0.25
EPS (Diluted) growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: -50.0%
EPS (Diluted) history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | −$0.25 | -50.0% | +$0.25 | ||
| 2024 | −$0.50 | -62.7% | +$0.84 | ||
| 2023 | −$1.34 | -37.1% | +$0.79 | ||
| 2022 | −$2.13 | +59.0% | −$0.79 | ||
| 2021 | −$1.34 | -36.5% | +$0.77 | ||
| 2020 | −$2.11 | -80.7% | +$8.81 | ||
| 2019 | −$10.92 | -93.1% | +$146.80 | ||
| 2018 | −$157.72 | -69.8% | +$364.19 | ||
| 2017 | −$521.91 | -44.1% | +$411.22 | ||
| 2016 | −$933.13 | +126.7% | −$521.58 | ||
| 2015 | −$411.55 | -59.7% | +$610.65 | ||
| 2014 | −$1.02K | -96.0% | +$24.48K | ||
| 2013 | −$25.50K | +1266.4% | −$23.63K | ||
| 2012 | −$1.87K | +77.1% | −$812.44 | ||
| 2011 | −$1.05K | -51.6% | +$1.12K | ||
| 2010 | −$2.18K | -42.4% | +$1.61K | ||
| 2009 | −$3.78K | +8.5% | −$296.43 | ||
| 2008 | −$3.49K | +20.5% | −$593.27 | ||
| 2007 | −$2.89K | +354.8% | −$2.26K | ||
| 2006 | −$636.24 | — | — |
- 2025−$0.25-50.0%
- 2024−$0.50-62.7%
- 2023−$1.34-37.1%
- 2022−$2.13+59.0%
- 2021−$1.34-36.5%
- 2020−$2.11-80.7%
- 2019−$10.92-93.1%
- 2018−$157.72-69.8%
- 2017−$521.91-44.1%
- 2016−$933.13+126.7%
- 2015−$411.55-59.7%
- 2014−$1.02K-96.0%
- 2013−$25.50K+1266.4%
- 2012−$1.87K+77.1%
- 2011−$1.05K-51.6%
- 2010−$2.18K-42.4%
- 2009−$3.78K+8.5%
- 2008−$3.49K+20.5%
- 2007−$2.89K+354.8%
- 2006−$636.24—
EPS (Diluted) values are taken from SELLAS Life Sciences Group's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at SELLAS Life Sciences Group (SLS)
According to SELLAS Life Sciences Group's latest reported financial statements, the company's current diluted EPS (TTM) is −$0.23. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
SELLAS Life Sciences Group (SLS) most recent annual diluted EPS stands at −$0.25 (2025) – plunged 50.0% year-over-year.
The record annual diluted EPS stands at −$0.25, reached in 2025; the historical low of −$25.50K was recorded in 2013.
SELLAS Life Sciences Group EPS (Diluted) by Year
SELLAS Life Sciences Group EPS (Diluted) 2025: −$0.25
2025's diluted EPS for SELLAS Life Sciences Group came in at −$0.25, plunged 50.0% below 2024. This figure represents the highest annual value in the available history.
SELLAS Life Sciences Group EPS (Diluted) 2024: −$0.50
SELLAS Life Sciences Group posted diluted EPS of −$0.50 in 2024, plunged 62.7% below 2023.
SELLAS Life Sciences Group EPS (Diluted) 2023: −$1.34
In 2023, SELLAS Life Sciences Group reported diluted EPS of −$1.34, plunged 37.1% below 2022.
SELLAS Life Sciences Group EPS (Diluted) 2022: −$2.13
SELLAS Life Sciences Group diluted EPS in 2022 was −$2.13, surged 59.0% from 2021.
SELLAS Life Sciences Group EPS (Diluted) 2021: −$1.34
SELLAS Life Sciences Group diluted EPS in 2021 was −$1.34.
See more financial history for SELLAS Life Sciences Group (SLS). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation